Video of Investor Jim Mellon Presenting at Abundance 360 Summit 2019
Jim Mellon's Juvenescence venture is at present one of the few major venture organizations focused on approaches to treat aging as a medical condition. Mellon and his colleagues outlined their take on the field in a 2017 book, also called Juvenescence. We are fortunate in that he is among the first few high net worth individuals to both agree with the SENS philosophy of damage repair, and then, much more importantly, follow through in action as well as word. He is not just seeing a massive market opportunity in treating aging, though that is certainly there, but is doing this because he wishes to achieve the goal of radical life extension - far longer, healthier lives for all. Jim Mellon is a relentless promoter once he has entered a field. As the science progresses to clinical development, we need someone like this. He will pull in the largest, most conservative investment concerns who presently have next to no interest in treating aging, and his funds will enable the startups and development programs needed to produce therapies. This is the necessary next stage in the evolution of rejuvenation research and development: moving from the laboratory to the clinic, moving from startup with data to fully funded company with human trials underway. It is an enormous amount of work, and requires large amounts of funding. That funding doesn't just happen my magic; considerable effort goes into lining up all of the necessary moving parts. Jim Mellon - Abundance 360 Summi...
Conclusions This study demonstrated a limited role of continuous passive motion in patients operated with total knee arthroplasty. Thus, there is at this stage no indication for continuous passive motion procedures in patients operated with total knee arthroplasty as a standard postoperative care.
In response to increasing dependence on US Medical Licensing Examination Step 1 scores for resident selection, and to improve medical student well-being and education, the Federation of State Medical Boards and the National Board of Medical Examiners announced that no sooner than 2022, Step 1 score reporting would change from numeric to pass/fail. To gauge the impact that this change will have on the residency application process in physical medicine and rehabilitation, an anonymous survey was electronically distributed to program directors of all accredited physical medicine and rehabilitation residency programs in the Un...
No abstract available
Link to case here: Liver Failure [Medication-Induced] This case has an expert witness opinion from a GI doc. Patient was started on Depakote, LFTs were initially fine. Within 5 weeks she had a liver transplant. The expert notes that she had positive ASMA and ANA titers and homozygous positive for H63D hemochromatosis. Do these results suggest that there may be an alternative cause for her liver failure?
Conclusions: Two-way messaging and standardized documentation increased rates. Declinations persisted despite education. Reasons included fear of side effects, and rarely leaving home due to the COVID-19 pandemic. Nursing interventions can increase influenza vaccination quality measures for primary care home telehealth patients.
Conclusions: Changes could be due to individual state practices.
HEART disease: Around twice as many people are living with heart and circulatory diseases in the UK than with cancer and Alzheimer's disease combined according to the British Heart Foundation. Could a seemingly innocent and popular drug be contributing to these shocking statistics?
AbstractAdditional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.
France has just made boosters available for everyone over 18, as long as it has been 5 months since their second dose. Those who are not vaccinated by mid-January risk losing their pass sanitaire.Medscape Medical News
AbstractMore than 12 months have passed since the World Health Organization (WHO) declared Coronavirus Disease 19 (COVID-19), caused by the SARS-CoV2 virus, to be a pandemic on 11 March 2020. The entire world scientific community agrees that at this time vaccine is the most promising weapon to combat the infection and the severity of the disease. According to the document “Draft landscape of COVID-19 candidate vaccines” by WHO, 272 vaccines against SARS-CoV-2 virus are in development, although only four of these, produced by Pfizer-BioNTech (Pfizer, Inc. and BioNTech), Moderna, AstraZeneca, and Janssen companie...
More News: Addiction | Age-Related Macular Degeneration (AMD) | Biology | Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Cardiology | Chocolate | Conferences | Environmental Health | Fortamet | Funding | Fundraising | Gastroschisis Repair | Gene Therapy | Genetics | Germany Health | Headache | Heart | Heart Transplant | Hepatitis | Hepatitis C | Hepatitis Vaccine | Immunotherapy | Internet | Laboratory Medicine | Learning | Liver | Liver Transplant | Men | Metformin | Migraine | Orthopaedics | Osteoarthritis | Osteoporosis | Pfizer | Science | Sports Medicine | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants | Universities & Medical Training | Urology & Nephrology | USA Health | Vaccines | Veterinary Vaccinations | Women